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Background: Proton-beam radiotherapy (PBT) has been shown to be effective to hepatocellular carcinoma (HCC)
as a nonsurgical local treatment option. However, HCC still remains as one of the most difficult cancers to be cured
because of frequent recurrences. Thus, methods to inhibit the recurrence need to be explored. To prevent the HCC
recurrence, we here report on a prospective phase I study of ‘in situ’ tumor vaccination using CalTUMP, a newly
developed immunoadjuvant consisting of BCG extract bound to hydroxyapatite and microparticulated tuberculin,
following local PBT for HCC.
Methods: Patients with locally advanced recurrent HCC, which had been heavily pretreated with various
treatments, were enrolled. PBT was performed with the conventional method to the target HCC. Subsequently,
CalTUMP was injected into the same irradiated-tumor three times at one-week intervals. Three dose-levels of
CalTUMP (1/10, 1/3, and 1/1) were administered to 3 patients each. Vital signs, blood samples, ultrasound, and
computed tomographic scans were monitored to evaluate the safety.
Results: Three intratumoral injections of CalTUMP following PBT (median dose: 72.6 GyE) were accomplished in 9
patients. Transient low-grade fever and minor laboratory changes were observed in 7 patients after CalTUMP
injections. No other treatment-related adverse events were observed. Median progression-free survival was
6.0 months (range: 2.1-14.2) and 4 patients were progression-free for more than 1 year.
Conclusions: Intratumoral injection of CalTUMP following PBT was feasible and safe in patients with heavily
pre-treated HCC. Further clinical studies to evaluate the efficacy of this in situ tumor vaccination are warranted.
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Hepatocellular carcinoma (HCC) is the second leading
cause of cancer-related deaths with approximately 750,000
new cases reported per year in the world [1,2]. The major-
ity of HCC occurs in patients who developed liver cirrhosis
secondary to chronic hepatitis B or C infections, alcohol
abuse, or nonalcoholic steatohepatitis. In the past few* Correspondence: tsuboi-k@md.tsukuba.ac.jp
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reproduction in any medium, provided the ordecades, multimodal treatments of HCC, including surgical
hepatectomy, radio-frequency ablation (RFA), transarterial
chemoembolization (TACE), liver transplantation, and a
molecular target-drug, sorafenib, etc. [3,4], have much
progressed with consensus guidelines published by several
organizations [5-7].
Despite these advances in the treatment, HCC still re-
mains as one of the most difficult cancers to be cured, be-
cause multiple recurrences of the tumor are quite
frequent [3-7]. Thus, methods that can effectively prevent
the recurrence need to be explored rigorously. In addition,d. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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hepatitis C virus infected during 1950′ to 80′, many HCC
patients are now aged more than 75 years old and have
limited treatment options or often cannot receive treat-
ments recommended by the guidelines.
Radiotherapy (RT) had not been successful for HCC
until late 1980′s, because only insufficient doses
(<30 Gy) could be applied to the cirrhotic liver to avoid
fetal radiation-induced liver disease (RILD). Proton
beam, unlike conventional X-ray, forms a unique Bragg
peak ionization that enables ‘tumor-targeted irradiation’
[8]. Based on this unique property, we have introduced
proton beam therapy (PBT) for HCC since 1983, in col-
laboration with the High Energy Accelerator Research
Organization at Tsukuba, and demonstrated the first
evidence of curative yet safe radiotherapy for HCC [9].
Subsequently, we observed an excellent 5-year local
tumor control rate of 87% and a 5-year overall survival
of 24% in the first 168 HCC patients treated with PBT
[10]. Patients with solitary HCC and Child-A liver func-
tion were associated with a good 5-year survival of
53.5% [10], which was comparable to the results of sur-
gical resection [11]. We then opened an in-house PBT
facility at Tsukuba University Hospital in 2001, and
could demonstrate its excellent local tumor control rate
(83%) and further improved 5-year survival rate (44.6%)
in HCC patients [12]. Since PBT is safe and has limited
effects on liver function [13], we especially recommend
it to aged HCC patients [14] who prefer not to take the
risk of surgery or to patients with limited treatment op-
tions due to various extrahepatic complications [15] or
poor liver function [16]. We have also reported on its
excellent efficacy for large HCC (> 5 cm) [17], HCC
with portal vein tumor thrombosis (PVTT) [18], HCC
adjacent to porta-hepatis [19] or alimentary tracts [20].
In addition, PBT can be further intensified by hypo-
fractionation [21] and can be repeated safely [22]. Fol-
lowing these preceding clinical data of ours, a high
efficacy of PBT for HCC has been confirmed by other
newly developed PBT facilities [23-26]. The recent in-
crease of PBT facilities worldwide may indicate that
more HCC patients, especially elderly patients or those
with complications, will be treated by PBT in the
near future.
However, HCC patients who receive PBT, as well as
those receiving other therapies, are not free from the
high incidence of recurrences. In fact, the intra-hepatic
extra-field recurrence following PBT is frequent: almost
50% at 1 year and 85% after 5 years [11,13]. In spite of
additional localized therapies, most patients eventually
suffer fatal hepatic failure due to repeated multiple re-
currences. Therefore, prevention of intra-hepatic recur-
rence is clearly the most critical issue in improving the
survival of patients with HCC.One promising option in preventing recurrence is tumor
immunotherapy. We have previously reported on a phase
II randomized clinical trial in which we demonstrated that
autologous formalin-fixed tumor vaccine (AFTV) made
from resected tumor tissue significantly improved both
overall and event-free survivals after surgery [27]. Al-
though the results strongly suggest that AFTV is effective
in preventing the recurrence of HCC, treatment availabil-
ity is limited by the fact that a certain volume of autolo-
gous cancer tissue is required to produce the vaccine [28].
To overcome this limitation, we postulated that utilizing
in vivo tumor tissue following local treatments, such as
RFA or radiation, would enable us to induce a systemic
immune response against the tumor.
Based on this idea, we report here the first clinical trial
to test the efficacy of “in situ vaccination” approach using
hydroxyapatite (HA; Ca10(PO4)6(OH)2) immune adjuvant
injected into the tumor tissues, which were pretreated
with the potent PBT. Our primary endpoints was to con-
firm the safety and the secondary endpoint was to evaluate
the efficacy of PBT followed by direct intratumoral injec-
tion of HA adjuvant in patients with HCC. This novel ap-
proach combining confocal radiotherapy and systemic
immunotherapy complements the drawbacks of each




A prospective one-arm Phase I clinical trial was designed to
evaluate the safety and efficacy of PBT followed by echo-
guided direct intratumoral injection of a newly developed
immunoadjuvant named “CalTUMP”, an HA adjuvant, in
patients with HCC as illustrated in Figure 1. HA adjuvant
dosage was increased incrementally as indicated in Table 1.
Patient selection
Subjects were chosen from recurrent cases of locally ad-
vanced HCC who still retained their hepatic function. Eli-
gibility criteria were as follows: 1) A pathological or
radiological diagnosis of HCC. 2) Locally advanced HCC
that recurred after standard therapy, with indications for
additional PBT. 3) Quantifiable tumor size. 4) A life ex-
pectancy >6 months. 5) Adequate hepatic function to
undergo PBT. 6) Adequate bone marrow function to
undergo PBT. 7) Normal renal function (Serum cre-
atinine < 1.5 mg/dL). 8) Karnofsky Performance Scale
(KPS) 80% or higher. 9) Aged between 20 and 80. 10)
Acknowledges the diagnosis and has given written in-
formed consent. 11) Patients whose follow-up is pos-
sible at the University Hospital of Tsukuba or its
affiliated hospitals.
The exclusion criteria were as follows: 1) History of ma-
lignancy other than HCC within the last 5 years. 2) A
Figure 1 Treatment schedule. One treatment course comprises of proton beam radiotherapy (PBT) and 3 echo guided injections of CalTUMP
every week. Delayed hypersensitivity test (DTH) using CalTUMP was performed 5–7 days after PBT. The first intratumoral injection of CalTUMP was
performed 48 hours after DTH. The follow-up period was more than 1 year.
Abei et al. Radiation Oncology 2013, 8:239 Page 3 of 10
http://www.ro-journal.com/content/8/1/239history of autoimmune disease. 3) Human immunodefi-
ciency virus (HIV) infection. 4) Presence of complications
including hematologic disorders or bleeding tendencies,
which could disrupt protocol requirements. 5) Uncon-
trolled disease including serious infections, and cardiac or
psychiatric disorders. 6) Presence of Grade 3 or higher
bone marrow dysfunction as specified in the Common
Terminology Criteria for Adverse Events (CTCAE v3.0)
[29]. 7) Use of antineoplastics or corticosteroids within the
last 4 weeks, systemic radiotherapy, or biological therapy. 8)
Pregnant or intent to become pregnant. 9) Tuberculosis or
skin reaction to CalTUMP exhibiting an induration >2 cm
in the delayed hypersensitivity test. 10) Patients with condi-
tions deemed unsuitable for inclusion in this study by the
physicians in charge.
Proton beam irradiation
PBT was conducted based on the computed tomography
(CT) images taken at 5-mm intervals at the treatment site.
A booster synchrotron generating 250 MeV proton beams
at the Proton Medical Research Center (PMRC) was used.
Dose distribution and settings for the collimator configur-
ation, bolus, and range-shifter thickness were determined
from the treatment plan. The relative biological effective-
ness (RBE) of the PBT was assumed to be 1.1 [30]. Clinical





Size and number of tum
Location (Size)
1 73/M A (5) S4/5/8 (110 mm), S5/6 (8 mm), Lymph node (1
2 55/M A (6) S3 (34 mm), S4 (58 mm, 8 mm), S8 (10 m
3 52/M A (5) right lobe (110 mm), S3 (44 mm, 70 mm
4 63/M A (5) S1 (26 mm, 18 mm), portal region (19 mm
5 65/M B (8) S4 (87 mm), S5/7/8 (10 mm× 4)
6 65/M A (5) S5 (54 mm), S1 (27 mm), S4 (8 mm) lateral se
of left lobe (12 mm), Lymph node (12 mm
7 59/M A (6) S5/8 (20 mm)
8 72/M A (5) In the vicinity of IVC (46 mm)
9 71/F A (5) S8 (14 mm, 14 mm)
(LN: Lymph node, KPS: Karnofsky performance status, PBT: Proton beam radiotherapthe tumor on CT scans. Planned target area was defined as
the CTV area plus a 10-mm margin. Two treatment proto-
cols of 72.6 GyE in 22 fractions, and 74 GyE in 37 fractions
were applied. The total dose and fractions for each patient
are shown in Table 1.
Immunoadjuvant CalTUMP
A calcium phosphate solution (RSM) supersaturated with
respect to HA was prepared by mixing a 24.84 volume of
Ringer’s solution (Fuso Pharmaceutical Industries, Ltd,
Osaka, Japan) and a 3.72 volume of glucose-L-lactate-phos-
phate buffered saline (Ajinomoto Pharmaceuticals, Co.
Ltd., Tokyo, Japan), with a 0.287 volume of 7% sodium bi-
carbonate (Otsuka Pharmaceutical Factory, Ltd., Naruto,
Kochi, Japan). The RSM solution was further mixed with a
1/10th volume of ethanol and incubated at 50°C overnight.
Resulting HA nanoparticles and their aggregated precipi-
tates were collected via centrifugation at 1,200G for
15 min, and then washed with RSM solution. One ml of
BCG extract was prepared by adding alcohol to 24 mg of
freeze-dried BCG vaccine (Japan BCG Laboratory, Tokyo,
Japan). The packed HA was resuspended in RSM solution
and adjusted to a 3.4%(v/v), and a 10%(v/v) BCG extract
was added. The mixture was incubated at 37°C for one
day to coprecipitate BCG extract with HA on the HA




0 mm) 3 (1) 90 74 GyE/37f 1/10
m) 4 (0) 90 72 GyE/37f 1/10
) 3 (0) 90 72.6 GyE/22f 1/10
) 3 (0) 90 72.6 GyE/22f 1/3
5 (0) 90 52.8 GyE/16f 1/3
gment
)
5 (1) 90 87.6 GyE/27f 1/3
1 (0) 100 72.6 GyE/22f 1/1
1 (0) 90 72.6 GyE/22f 1/1
2 (0) 100 72.6 GyE/22f 1/1
y, Dose.frac: Total dose/fraction number).
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particles (TUMP) were prepared according to a previ-
ously described method using 125 ng of PPD instead of
106 U of IL-2 [28].
Dose of CalTUMP in this study was defined as fol-
lows; concentration of 1/1 corresponding to dose-3 was
constructed with HA loaded with BCG extract at 3.2%
(v/v, as the packed volume), TUMP at (as PPD) 125 mg/mL,
and 0.01% human serum albumin in RSM solution. The
final suspension contained 2.23 mg/ml of calcium ion as
quantified by inductively coupled plasma-atomic emission
spectroscopy. CalTUMP was diluted with 0.01% human
serum albumin in RSM solution to 1/10 for dose level 1
and by 1/3 for dose level 2.
Intratumoral injection of CalTUMP
Five to seven days after the end of PBT, a 1/10 dilution
of CalTUMP was injected intradermally to test it for
hypersensitivity and safety. Confirming that the skin in-
duration was less than 2 cm after 48 hours, CalTUMP
was injected directly into the tumor site under local
anesthesia, guided by ultrasound imaging. Patients were
injected a total of 3 times at 7-day intervals. As indicated
in Table 1, each patient received 3 treatments with one
of the 3 dose levels (1/10, 1/3 or 1/1) of CalTUMP. Each
dose level was tested in 3 subjects each.Evaluation
The primary endpoint of this trial was to determine the
safety of this combined treatment. Clinical symptoms and
laboratory data were evaluated in accordance with the
Common Terminology Criteria for Adverse Events
(CTCAE v3.0) [29]. Blood and urine samples were col-
lected before and after PBT, after the 3rd CalTUMP injec-
tion, 2 weeks later, and then every 2 months thereafter.
Complete blood counts, serum levels of c-reactive protein
(CRP), and urinalyses were followed. Tumor markers in-
cluding lens culinaris agglutinin-reactive fraction of alpha-
fetoprotein (AFP-L3 fraction), protein induced by vitamin
K absence or antagonist (PIVKA)-II, carcinoembryonic
antigen (CEA), pancreatic cancer associated antigen
(DUPAN-2), carbohydrate antigen (CA) 19–9 were moni-
tored, and ultrasounds were taken at these sampling
points. Computed tomography (CT) of the lung and abdo-
men was conducted to exclude possible embolic or
hemorrhagic complications on the day following the third
CalTUMP injection. Tumor size was evaluated in accord-
ance with the Response Evaluation Criteria in Solid
Tumors (RECIST) guidelines [31].
Secondary endpoints were as follows: 1) Time to disease
progression, 2) Cause specific survival, 3) Overall survival,
4) Quality of life as measured by Karnofsky Performance
Scale (KPS) [32].Ethics
This clinical trial was approved by the Committee for
Medical Ethics at the University Hospital of Tsukuba.
Prior to initiating any procedure related to the protocol,
written informed consent was obtained from every patient,
and patient wishes and consent were respected in all in-
stances. In addition, the Critical Path Research and Educa-
tion Integrated Leading Center, University Hospital of
Tsukuba accepted the monitoring of protocol compliance
and patients’ status independently. We registered this
study in the University Hospital Medical Information Net-
work Clinical Trials Registry (UMIN-CTR) Japan (identifi-
cation # 000002863, Tokyo).Results
Between September 2009 and December 2010, 9 patients
(8 men and 1 woman) who met the inclusion criteria were
enrolled in this clinical study as shown in Table 1. The en-
tire clinical courses of these 9 patients are summarized in
Figure 2. At the time of this analysis, 6 patients had died
of HCC recurrence (#1,2,4,5,6,8), 2 patients were alive, but
had recurrent tumors (#3, 7) and 1 patient was alive with
no evidence of recurrence (#9).
Safety
Every patient tolerated the treatment well and was able to
complete the entire protocol with the exception of one pa-
tient (#5) in whom PBT was suspended at 52.8 GyE/16
fractions due to an increase in ascites. However, intra-
tumoral injections of CalTUMP were performed as
planned. In case #6, 15 GyE/5 fractions were boosted to
the tumor at S5 to compensate for the 20% dose inad-
equacy in the initial treatment plan (Table 1). Acute tox-
icity related to PBT was observed in all patients: radiation
dermatitis with G2, slight increases of SGOT and SGPT in
one patient (#3), a temporary increase of bilirubin in one
(#5), and a temporary increase of BUN and creatinine in
one (#6). All laboratory data subsequently normalized
without any clinical manifestations. As for the toxicity as-
sociated with intratumoral injections of CalTUMP, 7 pa-
tients (# 1, 2, 3, 4, 6, 7, 9) showed some low-grade fever
between 37.1 and 38.4 as shown in Table 2. Laboratory
data after injections showed a slight increase of CRP in 3
cases (#1,2,7), a decrease of PT in one (#5) and increases
of SAST, SALT, γ-GTP, ALP and CRP in one (#9). Labora-
tory changes were temporary and required no medical
intervention. No hemorrhagic or infectious complication
related to treatment was noted. In addition, CT scans
taken on the day after the final intratumoral injection,
demonstrated no evidence of lung or abdominal complica-
tions. Although we escalated dose of CalTUMP from 1/10
to 1/1, there was no significant increase of adverse effects
associated with this dose escalation.
Figure 2 Clinical courses of 9 patients. Clinical courses of 9 cases are illustrated. Upward-arrows indicate recurrence or metastasis, and
numbers indicate duration (months) after the initiation of PBT. Numbers at the right end of bars indicate follow-up duration in months by the
end of March 2012.
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jections were listed. Cause of death in 6 patients who
died during the follow-up periods were listed.
The direct cause of death in 6 patients was hepatic fail-
ure due to HCC progression. The three cases (#2,5,8) who
died within 12 months of the final injection were critically
reviewed by two independent safety and efficacy commit-
tee members. Both concluded that the deaths in these
cases were due to HCC progression, and the causality of
the treatment was deemed minimal or unrelated.
These results suggest that the toxicity associated with
PBT was of the same level as previously reported [33]. In
addition, the adverse effects of intratumoral injections of
CalTUMP were shown to be within tolerable limits. How-
ever, maximum tolerant dose of CalTUMP was not deter-
mined as there was no significant correlation between
occurrence of toxicity events and dose of CalTUMP.
Efficacy
Recurrent disease was seen in one patient (#2) immedi-
ately after PBT and two patients (#5, #8) immediatelyafter the third injection of CalTUMP. These three had
significantly shorter survival times as compared to 6
other cases including 4 cases (#1,4,7,9) who were recur-
rence free for more than one year from the initiation of
PBT (Figure 2). As there was no constraint on selection of
treatment after recurrence, patients #3, 7 underwent mul-
tiple sessions of transarterial chemoembolization, patients
#2, 6, 8 received chemotherapy consisting of either cis-
platin, gemcitabine or tegafur/gimeracil/oteracil (TS-1),
and patients #3, 8 were treated with sorafenib. Case #9 re-
ceived AFTV [28] as per her wishes 7 months after the
3rd injection of CalTUMP without noticing recurrence,
and has thus far shown no evidence of progression, and is
currently stable.
Discussion
In the present phase-I clinical trial, we could demon-
strate that the direct intratumoral injection of the newly
developed immunoadjuvant, CalTUMP, for inducing
in situ tumor vaccination after PBT was both feasible and
safe in patients with HCC. We are now planning a phase
Table 2 Acute toxicity and cause of death
No Age/gender PBT dose/frac Skin Labo data-1 CalTUMP dose Vital sign changes Labo data-2 Cause of death
1 73/M 74 GyE/37f G2 n.p. 1/10 I. None Slight increase of CRP HF due to HCC progression
II. 37.0-37.7 in 1–2 days
III. 37.1-37.5 in 1–2 days
2 55/M 74 GyE/37 f G2 n.p. 1/10 I. 37.4 in 1 day Slight increase of CRP HF due to HCC progression
II. None
III. None
3 52/M 76.2 GyE/22 f G2 Slight increase of SGOT, SGPT 1/10 I. 37.1 in 1 day n.p. n.p.
II. None
III. None
4 63/M 76.2 GyE/22 f G2 n.p. 1/3 I. None n.p. HF due to HCC progression
II. None
III. 37.4-37.7 in 1–2 days
5 65/M 52.8 GyE/16 f G2 Increase of Bil 1/3 I. None Decrease of PT HF due to HCC progression
II. None
III. None
6 65/M 87.6 GyE/27 f G2 Increase of BUN, creat 1/3 I. None n.p. HF due to HCC progression
II. None
III. 37.4 in 1 day
7 59/M 76.2 GyE/22 f G2 n.p. 1/1 I. 37.4 - 38.0 in 1 day Slight increase of CRP n.p.
II. 37.5 - 38.4 in 1 day
III. 37.7 in 1 day
8 72/M 76.2 GyE/22 f G2 n.p. 1/1 I. None n.p. HF due to HCC progression
II. None
III. None
9 71/F 76.2 GyE/22 f G2 n.p. 1/1 I. 37.0 in 1 day Increase of SGOT, SGPT, γ-GTP, ALP, CRP n.p.
II. 37.1 in 1 day
III. 37.8 on the same day
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the efficacy of this approach.
Several strategies have been tried to prevent the recur-
rence of HCC. Among them, retinoic acid [34] and
interferon-alpha [35] have shown efficacy in preventing
HCC recurrence after surgical resection. We have previ-
ously reported in a randomized clinical trial that active im-
munotherapy using AFTV successfully prolonged both
overall and progression-free survivals after surgical resec-
tion of HCC [27]. AFTV was also effective in patients with
glioblastoma multiforme (GBM) prolonging survival pe-
riods to 19.8 months or more [36,37]. Although the sam-
ple sizes in these reports were small, the results were
favorable as compared to the median overall survival of
14.6 months achieved by the GBM standard therapy
consisting of primary resection, radiation therapy plus
temozolomide administration [38].
However, a major drawback of AFTV is that it can be
applied only to the patients who have at least 1.5 gram
of surgically resected autologous tumor tissues. In order
to overcome this limitation, we have developed an in
situ vaccination in a mouse model, directly injecting
a microparticulated cytokine immunoadjuvant into
microwave-denatured established tumors [39]. The
injected adjuvant not only suppressed local recurrence
at the primary tumor site, but also tumor formation at
a differently challenged site. Theoretically, it may be
possible to induce a systemic immune response called
abscopal effect when the AFTV immunoadjuvant is ap-
plied to the in vivo denatured tumor site, which can be
referred to as in situ vaccination.
It has been reported that ionizing radiation up-regulated
immunological cell surface molecules such as ICAM-1,
CEA, and mucin-1 on human cancer cells in vitro [40,41].
In addition, we have previously reported that x-ray irradi-
ation enhanced immunogenicity of tumor cells by up-
regulation of molecules such as Fas and MHC-I in human
brain tumor cells in vitro [42]. Furthermore, Apetoh et al.
reported that radiation-induced cell death released high
mobility group protein B1 that binds heat shock proteins
to toll-like receptor (TLR)-4 on antigen-presenting den-
dritic cells [43]. These reports suggest that a combination
of confocal radiotherapy and systemic immunotherapy is a
promising way to induce synergistic effects on solid neo-
plasms. In particular, we have demonstrated that PBT is
effective in the local control of HCC due to the excellent
dose conformity to the target while preserving surround-
ing normal tissue [10,12-17]. These characteristics of PBT
may suggest that PBT also has an advantage for preserving
potential immune reaction in the local tumor environment.
Based on these, a strategy of in situ vaccination com-
bining cytotoxic therapy and immunoactivation has been
explored. Brody et al. reported that focal low dose radio-
therapy to one of the tumor sites and injection of aTLR-9 agonist at the same site induced systemic tumor
specific immune response and demonstrated complete
or partial response in 4 of 15 patients with relapsed
B-cell lymphoma [44]. Although this favorable result
may be due to the nature of the high response rate of
B-cell lymphoma to passive or active immunotherapy,
they could demonstrate acceptable feasibility and efficacy
of in situ vaccination in patients with relapsed B-cell
lymphoma burden. In our study, when the composition of
immunoadjuvant used for AFTV is delivered directly into
the tumor tissue and bound to denaturing (apoptotic/nec-
rotic) tumor cells after PBT, the immunoadjuvant-coated
tumor cell fragments are expected to become an in situ
tumor vaccine. Similar effects may possibly be expected
for patients with HCC treated by local ablation, as necrotic
or apoptotic tumor tissue left in situ are available as tumor
antigens. However, this treatment is not suitable for pa-
tients undergoing surgery because the tumor tissue is
removed.
Hydroxyapatite (HA; Ca10(PO4)6(OH)2) was used as a
sparingly soluble carrier of BCG extract to maintain bio-
activity at the injected site in this study. HA is a highly bio-
compatible material widely used as bone substitute since
its chemical composition and crystal structure closely re-
semble bone mineral. Thus, it has been substantiated
through clinical use as an osteoconductive bone substitute
for over three decades [45]. Furthermore, a clinical pilot
study was conducted using heated HA particles which had
adsorbed a patient’s self-tumor antigens [46]. It is known
that HA precipitated in an aqueous solution shows low
crystallinity, large surface areas and high adsorption nature,
while HA heated at high temperatures has high crystallin-
ity. Calcium phosphate adjuvant precipitated in a solution
with a Ca/P molar ratio of 1.0 has also been used in
humans as an immunoadjuvant for many years [47]. And
now, commercially available calcium phosphate adjuvant is
HA with a Ca/P molar ratio between 1.67 and 1.33 [48]. It
has been demonstrated that soluble bioactive molecules
coprecipitated with HA in a supersaturated calcium phos-
phate solution is released from HA in a sustained manner
and retain bioactivity [49,50].
Although we assumed that the percutaneous intra-
tumoral injection of CalTUMP might be associated with
some risks of adverse events such as hemorrhage, infec-
tion or needle track tumor seeding, we fortunately did
not observe any of these serious complications either in
examinations or laboratory data, indicating that this
procedure is both feasible and safe. The incidence of
needle tract tumor seeding associated with HCC biopsy
has been reported to be 3.4 to 5.1% [51,52]. However, the
incidence of seeding with our procedure would probably
be much lower, as no aspiration for tumor sampling was
performed, and centesis was done after the tumor was









































Over all survival  (n=9) 
Figure 3 Progression free (A) and overall (B) survival curves of the patients who underwent the protocol. Survival curves were drawn by
the Kaplan-Meier method.
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doses (1/10, 1/3, 1/1). Although it was shown that all 3
doses were tolerable, the occurrence of adverse effects was
not in a clear dose dependent manner. This might indicate
that we could not disclose the maximum tolerant dose of
CalTUMP in this study, and that adverse effects of the
immunoadjuvant may not be evaluable by a simple dose
escalation method. Further analysis is required.
With regard to the efficacy, we could not observe dra-
matic improvements in the outcome in some of our pa-
tients. It should be noted, however, that all patients in this
trial had highly advanced diseases with histories of either
multiple tumors or repeated recurrences. In 3 of the 9 pa-
tients, even extra-field liver or lymph node metastases were
found on imaging examinations immediately after PBT or
CalTUMP injections, strongly suggesting that minute re-
currences had already been existed before CalTUMP injec-
tion was started. The clinical recurrence of HCC is in
general composed of de novo carcinogenesis (true recur-
rence) and intra-hepatic metastasis. Therefore, in our next
phase II trial aimed at examining the efficacy of this ap-
proach, we should use a better inclusion criteria which
would allow us to select patients more suitable for examin-
ing the prevention effects of CalTUMP on the de novo car-
cinogenesis, such as those with the first and solitary
recurrence of HCC, and to exclude patients likely to have
already multiple metastatic tumors as some of the patients
in this trial. Another possibility for the lack of dramatic im-
provement in the outcome is the lack of adequate immune
response for those advanced stage patients, based on per-
ipheral blood samples and vital signs, suggesting that the
CalTUMP dose may have been insufficient. However, the
doses of CalTUMP used in this trial did induce non-
specific inflammatory responses such as transient fever or
increased levels of c-reactive protein (CRP) in 7 of the pa-
tients (#1, 2, 3, 4, 6, 7, 9), and the lack of these responses in
the remaining 2 (#5,8) was associated with a significantly
poorer prognosis (Table 2, Figure 3). Actually, we also tried
to evaluate the efficacy of this therapy by comparing overalland progression-free survival periods in a case-controlled
analysis. Ten patients in the control group for the com-
parative analysis were in the same stage and condition as
those receiving the combined therapy. Although the small
sample sizes prevented us from drawing any solid conclu-
sions, this comparative analysis did reveal a tendency for
prolonged progression-free survival in patients receiving
CalTUMP despite their median KPS being significantly
lower than that of the control group. In this study, we sim-
ply examined the survival rate and time to progression
from the last PBT followed by CalTUMP injection, regard-
less of the previous treatments performed before the last
PBT. The genuine efficacy of this in situ vaccine for the re-
duction of HCC recurrence should be examined in the fu-
ture by a randomized controlled trial with improved
patient selection criteria, where the effects of all potential
confounding factors, including previous treatments, can be
eliminated through randomization.
In conclusion, direct intratumoral injection of CalTUMP
after PBT in patients with HCC was found to be both feas-
ible and safe. This approach is unique that it uses in situ
inactivated tumor tissue and a newly-developed immu-
noadjuvant to induce in situ vaccination. Establishing the
safety and efficacy of this therapeutic strategy may help pre-
vent HCC recurrence and also prove effectiveness against
other solid cancers.
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